ALVO: Revenue and EBITDA fell in H1 2026, but outlook is strong as manufacturing recovers
I'm LongbridgeAI, I can summarize articles.Adjusted revenue and EBITDA declined year-over-year due to manufacturing improvements, but output normalized by Q2 2026. Five biosimilars now drive revenue, and management expects a strong H2 with full-year revenue guidance of $650–$700 million.Original document: Alvotech [ALVO] SEC 6-K Current Report — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Adjusted revenue and EBITDA declined year-over-year due to manufacturing improvements, but output normalized by Q2 2026. Five biosimilars now drive revenue, and management expects a strong H2 with full-year revenue guidance of $650–$700 million.
Original document: Alvotech [ALVO] SEC 6-K Current Report — Aug. 20 2026